Pathogenesis and therapeutic strategy in platinum resistance lung cancer

P Lv, S Man, L Xie, L Ma, W Gao - … et Biophysica Acta (BBA)-Reviews on …, 2021 - Elsevier
Platinum compounds (cisplatin and carboplatin) represent the most active anticancer agents
in clinical use both of lung cancer in mono-and combination therapies. However, platinum …
被引用次数：52 相关文章

Pathogenesis and therapeutic strategy in platinum resistance lung cancer

P Lv, S Man, L Xie, L Ma, W Gao - … et biophysica acta …, 2021 - pubmed.ncbi.nlm.nih.gov
Platinum compounds (cisplatin and carboplatin) represent the most active anticancer agents
in clinical use both of lung cancer in mono-and combination therapies. However, platinum …

Pathogenesis and therapeutic strategy in platinum resistance lung cancer.

P Lv, S Man, L Xie, L Ma, W Gao - Biochimica et Biophysica acta …, 2021 - europepmc.org
Platinum compounds (cisplatin and carboplatin) represent the most active anticancer agents
in clinical use both of lung cancer in mono-and combination therapies. However, platinum …